Boothbay Fund Management
AXDX icon

Boothbay Fund Management’s Accelerate Diagnostics AXDX Stock Holding History

Boothbay Fund Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,453
Closed -$301K – 738
2016
Q4 		$301K Buy
1,453
+453
+45% +$108K 0.07% 401
2016
Q3 		$273K Buy
+1,000
New +$221K 0.06% 414

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ArrowMark Colorado Holdings
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
JP Morgan Private Wealth Advisors
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return

Boothbay Fund Management's AXDX Position: Q1 2017 in Review

Boothbay Fund Management sold out of Accelerate Diagnostics (AXDX) in Q1 2017, closing a stake of 1,453 shares — an estimated $301K sold.

Boothbay Fund Management first reported a position in AXDX in Q3 2016 and held it in 2 quarters. The position peaked at $301K in Q4 2016. 98 funds tracked by Wall St. Rank hold AXDX as of Q1 2017.

  • Boothbay Fund Management reported no remaining Accelerate Diagnostics position as of Q1 2017 after selling out during the quarter.
  • Boothbay Fund Management sold 1,453 Accelerate Diagnostics shares in Q1 2017, an estimated $301K.
  • Boothbay Fund Management first reported a position in Accelerate Diagnostics in Q3 2016 and held it in 2 quarters.
  • Boothbay Fund Management's Accelerate Diagnostics position peaked at $301K in Q4 2016.
  • 98 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2017.

Based on Boothbay Fund Management's 13F filing for Q1 2017, filed 15 May 2017.